Surgery, Gastroenterology and Oncology
Vol. 25, No. 4, Sept 2020
A Case of Hereditary Gastrointestinal Stromal Tumor (KIT Mutation p.Asp820Tyr) in a Portuguese Family and a Good Response to Imatinib - An Update
Vítor Devezas, Hugo Santos-Sousa, Silvestre Carneiro, Elisabete Barbosa, José Barbosa
Images in Clinical Medicine, Sept 2020
Article DOI: 10.21614/sgo-25-4-206
Gastrointestinal stromal tumors (GIST) are the most common mesenchymal tumors of the human gastrointestinal tract. They are derived from transformed neoplastic precursors of the interstitial cells of Cajal.
They account for 0.1% to 3% of all gastrointestinal cancers. Up to 20% of cancers of the small bowel are GISTs. Less than 5% of cases are associated with hereditary predisposition, like Neurofibromatosis type I, Carney syndrome, and Familial GIST syndrome. The latter, is a rare autosomal dominant genetic disorder originated by germline gain-of-function mutations of KIT or PDGFRA.
The study objectives were: to update the response to imatinib of family of our institution and review the families cases published in the literature with this syndrome. Review of the cases of Familial GIST syndrome published in literature and update of the only portuguese family be consultation of clinical processes. In the literature, we found 35 cases of unrelated families with this syndrome.
This report is also an update on the only portuguese family with this syndrome and a good response to imatinib. The role of imatinib was not established in cases of familial GIST syndrome. In our opinion, it seems wise to use 400 mg day for an indefinite period. The objective is disease control and hindering the development of additional lesions.

Full Text Sources: Download pdf
Abstract:   Abstract EN
Views: 2652


Watch Video Articles


For Authors



Journal Subscriptions

Current Issue

Dec 2025

Supplements

Instructions for authors
Online submission
Contact
ISSN: 2559 - 723X (print)

e-ISSN: 2601 - 1700 (online)

ISSN-L: 2559 - 723X

Journal Abbreviation: Surg. Gastroenterol. Oncol.

Surgery, Gastroenterology and Oncology (SGO) is indexed in:
  • SCOPUS
  • EBSCO
  • DOI/Crossref
  • Google Scholar
  • SCImago
  • Harvard Library
  • Open Academic Journals Index (OAJI)

Open Access Statement

Surgery, Gastroenterology and Oncology (SGO) is an open-access, peer-reviewed online journal published by Celsius Publishing House. The journal allows readers to read, download, copy, distribute, print, search, or link to the full text of its articles.

Journal Metrics

Time to first editorial decision: 25 days
Rejection rate: 61%
CiteScore: 0.2



Meetings and Courses in 2025
Meetings and Courses in 2024
Meetings and Courses in 2023
Meetings and Courses in 2022
Meetings and Courses in 2021
Meetings and Courses in 2020
Meetings and Courses in 2019
Verona expert meeting 2019

Creative Commons License
Surgery, Gastroenterology and Oncology applies the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits readers to copy and redistribute the material in any medium or format, remix, adapt, build upon the published works non-commercially, and license the derivative works on different terms, provided the original material is properly cited and the use is non-commercial. Please see: https://creativecommons.org/licenses/by-nc/4.0/
Publisher’s Note:
The opinions, statements, and data contained in article are solely those of the authors and not of Surgery, Gastroenterology and Oncology journal or the editors. Publisher and the editors disclaim responsibility for any damage resulting from any ideas, instructions, methods, or products referred to in the content.